Comparative Pharmacology
Head-to-head clinical analysis: MICROSUL versus SODIUM SULFACETAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MICROSUL versus SODIUM SULFACETAMIDE.
MICROSUL vs SODIUM SULFACETAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MICROSUL inhibits bacterial dihydropteroate synthase, preventing folate synthesis, and also acts as a competitive antagonist of para-aminobenzoic acid (PABA).
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Adult: 160 mg/800 mg (trimethoprim/sulfamethoxazole) orally every 12 hours for 14 days; intravenous dosing: 8-10 mg/kg/day (as trimethoprim) divided every 6, 8, or 12 hours.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
None Documented
None Documented
Terminal elimination half-life: 24-36 hours; prolonged in renal impairment
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category A/B
Sulfonamide Antibiotic
Sulfonamide Antibiotic